MRNA technology takes on autoimmune diseases in early trial
NCT ID NCT07388212
First seen Feb 05, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This early-phase study tests a new mRNA-based drug for people with relapsed autoimmune diseases. The drug targets two proteins (CD19 and BCMA) to clear the B cells and plasma cells that mistakenly attack the body. Up to 27 participants aged 18-70 will receive the treatment to find the safest dose and see if it can reset the immune system. The goal is to control the disease, not cure it, as ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.